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Abstract  
 
Improvements in databases have already impacted GPCR research. The  purpose of the 
review is to give a snapshot of the GPCR data available and provide utility examples  
Consequently, this review covers a small set of major databases, including UniProt for 
proteins, Ensembl for genes, ChEMBL for bioactive chemistry and SureChEMBL for patents.  
In addition, two portals are outlined, GPCRdb and the IUPHAR/BPS Guide to 
PHARMACOLOGY (GtoPdb) that are based on expert annotation. The former has an 
emphasis on structures, sequences, point mutations, analysis tools and visualisation. The 
latter focuses on endogenous GPCR ligands, pharmacological modulation, approved drugs  
clinical candidates and tool compounds.  Since data growth is accelerating, those embarking 
on GPCR projects should not only check databases but also recent journal and patent 
publications.  
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Introduction  
Over the last few decades, databases have moved from the periphery of the biomedical 
sciences to a central position [1].  This digitally-driven migration is in part due to data 
deposition requirements of journals,  improvements in content, usability, access, 
documentation and automated interoperability. This progress is having an increasing impact 
on both experimental and in silico research [2].  GPCR-related databases have been 
previously reported in detail up to 2013 [3].   This article focuses on a key set of open 
resources that have updated in the last three years (Fable 1).  Some of these have introductory 
and educational value but this is outside of the scope of this review.  It should also be noted 
that GPCR researchers may have divergent foci. For example, these could encompass 
receptor evolution, biochemical mechanisms (including de-orphanisation), disease 
involvement, drug discovery, chemical biology and clinical pharmacology.  A classification 
that can make matching to particular research interests easier is to divide databases into 
primary, secondary and tertiary (analogous to journal research reports, review articles and 
book chapters).  While this division is not strict, it is useful to indicate differences in scales of 
data collation as well as the balance between manual curation versus automated annotation.   
The selected sources are listed in Table 1.  The Endothelin A receptor (ETA receptor or  
ENDRA, see other synonyms in Table 1) will be used as a human GPCR example  since its 
associated database records have recently been reviewed [4]. 
 
Primary Databases 
Primary databases are associated with the direct deposition of experimental data at large 
scale. They rely heavily on automated annotation and are updated frequently. Their value lies 
in maximal coverage but they can be challenging to navigate.  The best known example is the  
GenBank repository for nucleic acid sequences [5]. This has 314 million entries from which 
“endothelin receptor” will retrieve 1518.   One of these is a 69Kb genomic DNA sequence 
(GenBank: AY422989)  that includes annotation of the ENDRA gene structure.  We can also 
find S63938,  an 1868 base pair placental mRNA, as one of the transcript depositions for 
ENDRA. The protein translation, also a GeneBank record, is an open reading frame (ORF) of 
427 amino acids designated AAB20278.  Within the coding exons we can find a single 
nucleotide polymorphism (SNP) designated as rs772147672  from the 145 million reference 
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entries  in the dbSNP database  [6]. It should be pointed out that 3D structures are also 
primary data. Since there is no ENDRA crystal structure (yet), we can use the recent example 
of  the M4 muscarinic acetylcholine receptor bound to tiotropium,  released as  PDB: 5DSG  
in March 2016  [7].  It should also be noted that PubChem can be considered  a primary 
chemistry resource with over 90 million structures [8]. Different query routes can be used to 
find bioactive small-molecules acting on ENDRA but the Entrez Gene identifier 1909 links to 
48 PubChem Compound Identifiers (CIDs).  Following the molecular details for GPCRs 
through primary databases, as illustrated in this paragraph, provides comprehensive and up to 
date coverage.  However, since this requires extensive bioinformatics expertise, users may 
prefer the integrated presentation of this data in secondary databases.     
 
Secondary Databases 
Secondary databases are value-added aggregations of primary data sources that use 
automated merging rules together with some manual curation.  They are typically orders of 
magnitude smaller than primary databases and consequently easier to navigate. Examples for 
proteins, genes, chemistry, patents and diseases are selected here, as judged on their 
reliability. The first is UniProtKB containing over 65 million proteins extracted from 
GenBank.  The  quality of the  ~0.5 million manually reviewed entries that constitute the 
Swiss-Prot section,  makes UniProt  the  first choice of GPCR secondary protein resources 
[9].  It massively reduces the redundancy in primary sources (e.g. multiple mRNAs, 
alternative splicing, polymorphisms, PDB structures, pathways and bioactive chemistry) 
since these are all merged as annotated features or links from a single protein entry. For the 
human ENDRA entry (P25101, EDNRA_HUMAN), 22 GenBank primary mRNA and 
genomic DNA entries are cross-referenced.   UniProt coverage can be assessed with the 
keyword "g protein-coupled receptor". This returns 101,227 non-reviewed (i.e. automatically 
annotated) and 3,250 manually reviewed (Swiss-Prot) entries, of which 830 are human. 
Adding the search restriction (NOT) "olfactory receptor" reduces this to 403.  
 
The chosen genome resource is the EBI/Sanger Centre Ensembl where  ENDRA can be 
selected via the identifier ENSG00000151617  [10]. Navigation (via zooming and track-
toggling) can be used to discern aspects of gene evolution, regulation, expression, splicing 
and variation.  Note that (with quality filtration) 23,277 dbSNP entries are mapped onto the 
ENDRA gene locus.  New versions of Ensembl, including gene (re)builds synchronised with 
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new genome assemblies and variation data, are released every three months. Given the 
relative stability of the human reference genome, GPCRs are likely to have a consistent 
genetic architecture (i.e. the same spacing between introns, exon and regulatory regions) 
between releases, However, releases can have minor coordinate changes as well as new 
annotations for splicing, polymorphisms, improved resolution of regulatory regions, disease 
associations and orthologue expansions (via more species).  
 
ChEMBL can be considered a secondary database with a focus on collating structure-activity 
relationship (SAR) data from the medicinal chemistry literature. Release 21 has extracted not 
only 1.1 million chemical structures and associated results from just over 62,000 papers  but 
also ~0.5 million imported from confirmatory PubChem BioAssays [11].  We can establish 
that 2,577 compounds are mapped to the target entry for ENDRA (CHEMBL252) and that 
231 (non-olfactory) human GPCRs have a ChEMBL link.  Note that ChEMBL submits 
structures and BioAssay data to PubChem within a few weeks of a new release. Given the 
importance of chemistry-to-GPCR mapping (as indicated by the other articles in this issue) 
we can also count mappings for three other bioactivity databases with UniProt cross-
references (Fig. 1).  
  
The DrugBank  [12] and BindingDB [13]  resources are described in recent publications. 
Differences in relationship mapping between ChEMBL and DrugBank have also been 
detailed [14], with ChEMBL recently publishing their own quality analysis [15].  Regardless 
of complexities (e.g. where interactions include endogenous ligands, exogenous peptides, 
clinical antibodies and some inactive results) Figure 1 indicates that ~2/3rds of the 403 non- 
olfactory GPCRs have some kind of activity modulators.  
 
In terms of bioactive chemistry, GPCR researchers may neither be aware that the patent 
corpus documents at least twice as much SAR as journal papers, nor that PubChem now 
contains over 20 million patent-extracted structures [16].  There are many options to retrieve 
GPCR-related patents but because the documents are linked to over 17 million structures  
SureChEMBL has become the secondary database of choice [17].  As an example, 
WO2009024906  from Actelion claims  CID 25099191 as an ENRA antagonist with a  3.4 
nM IC50 value, which was later published and extracted as CHEMBL2165326.  It also 
happens to be a metabolite of the approved ENDRA antagonist macitentan (CID 16004692).  
While searching patents remains a challenge for non-specialists, back-mapping is somewhat 
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easier. This means that for SAR published in a journal (e.g. captured by ChEMBL or GtoPdb) 
the structures can often be matched, via PubChem or SureChEMBL, back to an earlier patent 
publication with more data. Note also that SureChEMBL updates in situ within a week of 
patent publication.   
 
Of the database relationships GPCR researchers might want to explore, disease associations 
seem to be among the most challenging. Reasons include the absence of a primary sources 
equivalent to molecular data, the difficulty of integrating Mendelian disorders with the flood 
of genome-wide diseases association (GWAS) results  and problems of confirming  mutation-
to-phenotype causality [18].   Of the many  sources in this domain,  ClinVar is a useful 
secondary database that collates relationships from multiple sources of human variations and 
phenotypes, together with supporting evidence [19].  For ENDRA, 17 entries (including 
complex structural genomic variants) can be accessed via the link from the Entrez Gene ID 
1909  . However, the SwissProt ENDRA entry points just to three “Natural variant” amino 
acids exchanges, one of which is somatic rather than germline [20] . Given the acceleration in 
genome sequencing of all types of disease cohorts (including for rare diseases) an increase in 
GPCR variants with clinical effects is expected to be captured in ClinVar, and Swiss-Prot.  
 
Tertiary Databases 
 
While there is no clear division between secondary and tertiary sources, the latter integrate 
the former with a thematic focus.  They are also smaller scale, include a higher density of 
expert curation and - commensurate with their utility as first-stop portals -  have a strong 
focus on user navigation.  Two of these will be outlined here, GPCRdb [21]  [22] and the 
IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb) [23].  The selection criteria are a) 
they are well established, b) have detailed 2016 papers c) undergo frequent updates, d) 
directly collaborate on  complementary utility,  including web services compatibility  e) they 
extensively and reciprocally cross-point to other resource  f) are well documented and g) 
freely accessible.  
 
 The range of GPCRdb features includes the following; 
1. An emphasis on sequences, structural information  and analysis tools 
2. Manual curation of the core annotation  integrated with computationally-derived data 
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3. Alignments with ~ 18,000 orthologues from UniProt updated when new PDB 
structures become available 
4. These are used as templates to optimise alignments and standardise generic residue 
numbering (142 are loaded for 37 unique GPCRs so far) [24] 
5. In addition to literature extraction of experimental mutation data, users can directly 
submit standardised result sets.  
6. Displays to support mutagenesis work include snake-plots of mutant proximity to 
ligand binding sites and tables of positions across paralogues and orthologues.  
7. Additional representations assess ligand selectivity and  important interactions   
8. Pharmacophore analysis tools that use ligand fragments from PDB structures [25] 
9. Links to external GPCR modelling servers 
 
One of the key differences between GPCRdb and GtoPdb is that the latter covers all human 
target classes. The 2016.2 release (March) includes 14,327 curated interactions (mostly IC50, 
Ki, and Kd measurements) across 2,775 proteins and 8,400 ligands. The following points will 
highlight the GPCR content.        
1. The current release has 245 Human GPCR UniProt IDs with quantitative interactions 
for over 3,500 distinct ligands  
2. 105 ligands have additional interactions to non-GPCRs (e.g. transporters) 
3. GPCR-directed approved drugs, clinical candidates and tool compounds are included 
4. Relationships captured by expert manual curation include free-text comments 
5. Annotation is supported by target family subcommittees of the International Union of 
Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug 
Classification (NC-IUPHAR). The  60 GPCR subcommittees  involve  ~540 
contributing scientists 
6. Selective compounds for in vitro and in vivo experimentation are highlighted 
7. Inclusion of manually checked reciprocal links to key genomic, protein and small 
molecule resources (e.g. GPCRdb,  UniProt and PubChem) as well as a “Useful 
Links” page 
8. Monitoring de-orphanisation  and/or surrogate ligands for GPCRs 
9. Curation of major disease-associated clinical variants 
10. Source for the biennially published “Concise Guide to PHARMACOLOGY” series of 
reviews, including  2015/16: G protein-coupled receptors [26]  
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Both these tertiary resources not only welcome technical feedback on their entries but also 
present additional options for user engagement. For GtoPdb, investigators can take the 
opportunity to join NC-IUPHAR GPCR family-specific subcommittees and/or submit their 
newly published papers. GPCRdb can be contacted for the direct submission of pre-
publication mutagenesis data. 
 
 
 
Conclusions 
GPCR researchers have an expanding choice of databases from which limited selection is 
introduced here.  Those less familiar with sequences, protein structures and bioactive 
chemistry may find the navigation order tertiary > secondary > primary easier that the other 
way round, particularly as the two tertiary portals GPCRdb and GToPdb described provide 
“first-stop-shops” from either structure-centric or pharmacology-centric viewpoints.  
Notwithstanding, while they offer massive efficiency gains, users also need to be aware of the 
shortcomings of databases.  Particularly for GPCRs, it is clear that detailed review papers 
(including those published under the auspices of NC-IUPHAR) distil knowledge, 
perspectives, nomenclature details, pharmacological complexities and bioassay nuances that 
are difficult to distil into structured database records.  Users should also appreciate that 
database content lags behind journal publications (e.g. the MeSH term "Receptors, G-Protein-
Coupled” retrieves 7322 entries just for 2015) and secondary databases can only capture 
subsets of these (i.e.  PubMed, PubMed Central and European PubMed Central can be 
considered primary databases).   Consequently, where experimentation is being planned on 
the basis of database findings, it is prudent to check the newest primary data entries and 
monitor the recent literature.   
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Figure 1.  Comparing UniProt chemistry database cross-references for GPCRs.  The Venn 
diagram shows the overlaps and differences (GtoPdb = IUPHAR/BPS Guide to 
PHARMACOLOGY).  Three sources include activity data for the chemistry-to-protein 
interactions but DrugBank indicates only relationships.  Individual totals are given in the 
source labels. The sum of all four extends to 265 GPCRs with a 4-way consensus intersect of 
105.  
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Figure 2. Screenshot from the GPCRdb ENDRA entry 
(http://gpcrdb.org/protein/ednra_human/),  the coloured residue properties are displayed. 
Users can alternatively select 51 mutation data points to be indicated on the snake plot or 
tabulated with source link-outs.  
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Figure 3. Screen shot of selected panels from the GtoPdb ENDRA entry.  
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=219 
The contents panel list the curated relationships.  Below this is a section on gene and protein 
information with 25 out-links.  The lower section includes just six rows from 29 agonists and 
antagonists (hovering the mouse provides a key to the symbols) 
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*Of special interest 
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UniProt Consortium.  (9) Updates and new features. 
Yates A, et al (10) Includes new features for comparing GPCRs across species. 
Southan C et al (14) A detailed study of  four databases with GPCR-related content  
Southan C (16)  Outlining the "big bang" of patent  chemistry in PubChem.  
Papadatos G et al (17) Desciption of a leading patent extraction resource. 
Landrum MJ et al   (19) Expanding resource of clinically relevant genetic variants 
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Kim S, et al (15)  Largest primary source of small molecules and peptides acting on GPCRs, 
Bento et al (11) Describes large-scale extraction of medicinal chemistry data from papers. 
Isberg V et al (22) Report on new features, displays and tools. 
Southan C et al  (23) Content capture, relationship statistics and curation rules for GtoPdb 
Alexander SPH et al (26) A review snapshot of GPCR entries extracted from GtoPdb. 
 
